PD-Loma: a cancer entity with a shared sensitivity to the PD-1/PD-L1 pathway blockade

Clinical trials have now identified over 30 cancer histotypes with sensitivity to anti-PD-(L)1 therapies. It is the first time in oncology that a class of drugs has demonstrated such a wide spectrum of activity in monotherapy. This subgroup of cancers (‘PD-Lomas’) is driving the clinical research st...

Descripción completa

Detalles Bibliográficos
Autores principales: Hirsch, Laure, Zitvogel, Laurence, Eggermont, Alexander, Marabelle, Aurelien
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Editorial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6325162/
https://www.ncbi.nlm.nih.gov/pubmed/30413824
http://dx.doi.org/10.1038/s41416-018-0294-4
_version_ 1783386089541599232
author Hirsch, Laure
Zitvogel, Laurence
Eggermont, Alexander
Marabelle, Aurelien
author_facet Hirsch, Laure
Zitvogel, Laurence
Eggermont, Alexander
Marabelle, Aurelien
author_sort Hirsch, Laure
collection PubMed
description Clinical trials have now identified over 30 cancer histotypes with sensitivity to anti-PD-(L)1 therapies. It is the first time in oncology that a class of drugs has demonstrated such a wide spectrum of activity in monotherapy. This subgroup of cancers (‘PD-Lomas’) is driving the clinical research strategies for the next generation of combination immunotherapy.
format Online
Article
Text
id pubmed-6325162
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-63251622019-11-09 PD-Loma: a cancer entity with a shared sensitivity to the PD-1/PD-L1 pathway blockade Hirsch, Laure Zitvogel, Laurence Eggermont, Alexander Marabelle, Aurelien Br J Cancer Editorial Clinical trials have now identified over 30 cancer histotypes with sensitivity to anti-PD-(L)1 therapies. It is the first time in oncology that a class of drugs has demonstrated such a wide spectrum of activity in monotherapy. This subgroup of cancers (‘PD-Lomas’) is driving the clinical research strategies for the next generation of combination immunotherapy. Nature Publishing Group UK 2018-11-09 2019-01-08 /pmc/articles/PMC6325162/ /pubmed/30413824 http://dx.doi.org/10.1038/s41416-018-0294-4 Text en © Cancer Research UK 2018 https://creativecommons.org/licenses/by/4.0/Note: This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution 4.0 International (CC BY 4.0).
spellingShingle Editorial
Hirsch, Laure
Zitvogel, Laurence
Eggermont, Alexander
Marabelle, Aurelien
PD-Loma: a cancer entity with a shared sensitivity to the PD-1/PD-L1 pathway blockade
title PD-Loma: a cancer entity with a shared sensitivity to the PD-1/PD-L1 pathway blockade
title_full PD-Loma: a cancer entity with a shared sensitivity to the PD-1/PD-L1 pathway blockade
title_fullStr PD-Loma: a cancer entity with a shared sensitivity to the PD-1/PD-L1 pathway blockade
title_full_unstemmed PD-Loma: a cancer entity with a shared sensitivity to the PD-1/PD-L1 pathway blockade
title_short PD-Loma: a cancer entity with a shared sensitivity to the PD-1/PD-L1 pathway blockade
title_sort pd-loma: a cancer entity with a shared sensitivity to the pd-1/pd-l1 pathway blockade
topic Editorial
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6325162/
https://www.ncbi.nlm.nih.gov/pubmed/30413824
http://dx.doi.org/10.1038/s41416-018-0294-4
work_keys_str_mv AT hirschlaure pdlomaacancerentitywithasharedsensitivitytothepd1pdl1pathwayblockade
AT zitvogellaurence pdlomaacancerentitywithasharedsensitivitytothepd1pdl1pathwayblockade
AT eggermontalexander pdlomaacancerentitywithasharedsensitivitytothepd1pdl1pathwayblockade
AT marabelleaurelien pdlomaacancerentitywithasharedsensitivitytothepd1pdl1pathwayblockade

Ejemplares similares